Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2017—Ortho Clinical Diagnostics launched its Vitros NephroCheck test, a fully automated risk assessment tool for predicting acute kidney injury. The test has received CE mark clearance and is available for purchase in Europe and for use on Ortho’s Vitros Systems.
August 2017—Luminex received FDA clearance for the Aries Bordetella Assay for direct detection and identification of Bordetella pertussis and Bordetella parapertussis nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.
August 2017—Genoptix and Bionano Genomics announced an exclusive agreement to co-develop information-rich diagnostics for selected hematologic oncology indications in the United States using Bionano’s Saphyr system.
August 2017—Binding Site’s Immunologicals Group has added a number of monoclonal antibodies used for the clinical testing of human immunodeficiency virus to its line of in vitro diagnostic manufacturing and clinical research applications. The HIV P24 275, HIV P24 114, and HIV P24 9.23.11.8.9.4 anti-human monoclonal antibodies have been designed for use as an integral component within a number of enzyme immunoassay testing procedures.
August 2017—Techlab Inc. received FDA clearance for its E. Histolytica Quik Chek test, a rapid diagnostic test that specifically detects pathogenic E. histolytica and does not cross-react with nonpathogenic Entamoeba dispar.
August 2017—Siemens Healthineers has entered into a definitive agreement to acquire Epocal, a subsidiary of Alere. Epocal develops and provides point-of-care blood diagnostic systems for health care enterprises, including the epoc Blood Analysis System, a handheld, wireless testing solution.
August 2017—Qiagen has joined Cancer-ID, a public-private consortium of 36 partners from 13 countries that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.
July 2017—To define the current state of reagents and serological assay technology used to measure total human immunoglobulin E and IgE antibodies of defined allergen specificities in human blood, the Clinical and Laboratory Standards Institute published a revised document that focuses on IgE assay design and calibration, validation methods, quality assurance of assay reagents, quality control strategies, and clinical applications.
July 2017—Streck has signed distribution agreements with Anopoli Biomedical Systems, an Austrian distributor of life sciences, molecular diagnostics, and microarray products, and with Ngaio Diagnostics,
July 2017—Myriad Genetics has launched the EndoPredict test in the U.S. for patients with ER+ HER2- early stage breast cancer. EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy.
